Granulocyte–macrophage colony-stimulating factor, a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials.
[Nature Reviews Immunology]
Mateon Therapeutics has selected IQVIA to manage C001, a Phase II randomized, controlled, multi-center clinical study of OT-101.
Investigators report the room temperature X-ray structure of unliganded SARS-CoV-2 3CL Mpro, revealing the ligand-free structure of the active site and the conformation of the catalytic site cavity at near-physiological temperature.
Scientists analyzed placenta for the presence of SARS-CoV-2 through molecular and immunohistochemical assays and by and electron microscopy, and measured the maternal antibody response in blood to this infection.
[Journal of Clinical Investigation]
In April, a published study showed chloroquine could increase mortality in COVID-19 patients. Since then, they have been accused of poisoning their patients with a high dose of chloroquine just to give the drug—praised by US President Donald Trump and his Brazilian counterpart Jair Bolsonaro—a bad name.
Four key government health care officials said Tuesday that despite recent remarks from President Trump, they were never ordered to “slow down” diagnostic testing for Covid-19.
A report that dexamethasone, a commonly used corticosteroid, reduces death rates of COVID-19 by up to one-third was greeted with enthusiasm around the globe. It also raised a question: Will there be enough of the medication?
Scientists are well placed to help to hold back the tide of COVID-19 misinformation — but should they get involved in time-consuming, and sometimes bruising, efforts to do so, or just stick to doing good research?
Researchers studied 37 asymptomatic individuals in the Wanzhou District who were diagnosed with RT–PCR-confirmed SARS-CoV-2 infections but without any relevant clinical symptoms in the preceding 14 days and during hospitalization.
Researchers found that the monoclonal antibody CR3022 bound the receptor binding domain (RBD) tightly, neutralizing SARS-CoV-2 and report the crystal structure at 2.4 Å of the Fab/RBD complex.
[Cell Host & Microbe]
The pattern of pro-inflammatory cytokines induced in COVID-19 has similarities to those targeted in the treatment of rheumatoid arthritis. Several clinical studies are underway that test the effects of inhibiting IL-6, IL-1β or TNF or targeting cytokine signaling via Janus kinase inhibition in the treatment of COVID-19.
[Nature Reviews Rheumatology]